p53 Normal and p53 Abnormal Clear Cell Ovarian Carcinomas: Clinical Characteristics and Biomarker Profiles
Piret Hellberg, Annukka Pasanen, Jonna Similä-Maarala, Ralf Bützow, Heini Lassus · 2026
Read p53 Normal and p53 Abnormal Clear Cell Ovarian Carcinomas: Clinical Characteristics and Biomarker Profiles by Piret Hellberg, Annukka Pasanen, Jonna Similä-Maarala, Ralf Bützow, Heini Lassus (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13460317.txt.
Description
Piret Hellberg and colleagues test whether p53 status splits clear cell ovarian cancer into distinct subgroups in a 2026 study. A new gene classification proposes TP53 wild-type versus mutated clear cell carcinoma, yet stain-test check was needed. Clinic-and-lab factors, 12 stain-test markers and outlook were analysed in 132 clear cell ovarian cancers.
The p53 abnormal group fared worse in cancer survival and cancer-free survival, largely through higher stage and more frequent left-over tumour. Marker patterns also diverged: ARID1A loss and HNF1-beta presence marked p53 normal tumours, while p16 extra and hormone receptor presence marked p53 abnormal ones, with group-only outlook links. Cancer doctors gain support for two distinct subgroups with different body workings and outcomes.
Catalog record
| CREATOR | Piret Hellberg, Annukka Pasanen, Jonna Similä-Maarala, Ralf Bützow, Heini Lassus |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |